Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Bainey

Clinical Cardiac Electrophysiology Palm Harbor, FL Doctor of Osteopathy

NPI 1134554272 CMS profile 566236

4705 Alt 19 Ste B, Palm Harbor, FL 34683

Open in the dashboard

General payments

$51,685

356 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Bainey of Palm Harbor, FL is reported in the CMS Open Payments database as having received $51,685 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,560 47
2024 General $1,251 80
2023 General $640 47
2022 General $1,262 46
2021 General $2,237 46
2020 General $26,485 33
2019 General $18,251 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Bainey
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Adam Bainey were reported at $1,560. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Adam Bainey Clinical Cardiac Electrophysiology median Middle half National median
2019 $18,251 $2,361 $585–$8,260 $163
2020 $26,485 $993 $247–$4,351 $114
2021 $2,237 $1,185 $326–$4,739 $132
2022 $1,262 $2,073 $554–$6,789 $149
2023 $640 $2,568 $759–$8,159 $160
2024 $1,251 $2,557 $703–$7,403 $164
2025 $1,560 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $38,196 9 payments
  2. Boston Scientific Corporation $6,058 133 payments
  3. Abbott Laboratories $3,319 52 payments
  4. Medtronic, Inc. $1,375 79 payments
  5. Biosense Webster, Inc. $1,278 53 payments
  6. Biotronik Inc. $788 10 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $169 4 payments
  8. Atricure, Inc. $111 1 payment
  9. Medicure Pharma Inc. $74 1 payment
  10. CardioFocus, Inc. $64 1 payment
  11. Other $253 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $37,500 2 payments
  2. Food and Beverage $10,917 336 payments
  3. Travel and Lodging $2,242 9 payments
  4. Education $1,026 9 payments
Products named General payments · program years 2019–2025
  1. General Therapies $2,130 6 payments
  2. Ensite Cardiac Mapping System $1,642 20 payments
  3. Carto 3 $935 45 payments
  4. Micra $714 43 payments
  5. WATCHMAN Access System $539 9 payments
  6. Rhythmia $421 13 payments
  7. Rivacor $375 5 payments
  8. Solia $375 5 payments
  9. Edora $375 5 payments
  10. BioMonitor $375 5 payments
  11. Other $6,890 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

771

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$343,526

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

56.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 238 $227,668
Multaq Dronedarone Hcl Brand 50 $65,483
Xarelto Rivaroxaban Brand 48 $41,248
Pradaxa Dabigatran Etexilate Mesylate Brand 11 $2,132
Flecainide Acetate Generic 39 $1,473
Amiodarone Hcl Generic 101 $1,386
Metoprolol Succinate Generic 105 $942
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 19 $881
Bisoprolol Fumarate Generic 31 $780
Clopidogrel Clopidogrel Bisulfate Brand 49 $681

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$184,949

Medicare's payments for the services billed

Medicare patients

782

Average age 77

Services billed

3,050

338 women, 444 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 65%
Ischemic heart disease 53%
Arthritis 50%
Heart failure 39%
Chronic kidney disease 34%
Diabetes 28%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record